Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 7 Prophylaxis with danazol and comparison of location-related symptoms between women and men in 2012

From: Hereditary angioedema due to C1 - inhibitor deficiency in Switzerland: clinical characteristics and therapeutic modalities within a cohort study

Location of attacks All Women no prophylaxis vs. Danazol Men no prophylaxis vs. Danazol women vs. men
All No prophylaxis Danazol p-values All No prophylaxis Danazol p-values p-values
  104 57 31 13   47 28 13   
abdomen 68 (65 %) 40 (70 %) 24 (77 %) 6 (46 %) p = 0.042 28 (59 %) 15 (53 %) 9 (69 %) p = 0.344 p = 0.063
extremities 61 (59 %) 34 (60 %) 20 (64 %) 5 (38 %) p = 0.111 27 (57 %) 14 (50 %) 8 (61 %) p = 0.491 p = 0.157
trunk 22 (21 %) 15 (26 %) 8 (26 %) 3 (10 %) p = 0.849* 7 (15 %) 4 (14 %) 0 p = 0.288* p = 0.523*
face 22 (21 %) 14 (24 %) 8 (26 %) 2 (6 %) p = 0.697* 8 (17 %) 4 (14 %) 1 (8 %) p = 0.486** p = 0.709**
genitals 22 (21 %) 11 (19 %) 8 (26 %) 1 (3 %) p = 0.242* 11 (23 %) 5 (18 %) 3 (23 %) p = 0.692* p = 0.586*
headache 16 (15 %) 11 (19 %) 4 (13 %) 3 (10 %) p = 0.404* 5 (11 %) 4 (14 %) 0 p = 0.288* p = 0.509*
larynx 16 (15 %) 9 (16 %) 6 (19 %) 1 (3 %) p = 0.654 7 (15 %) 4 (14 %) 1 (8 %) p = 0.486** p = 0.700**
  1. * Fisher’s exact test, ** one-sided
  2. Number of patients who suffered from at least one attack in the individual location in 2012